Clinical Trials · NCT06309992
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Boehringer Ingelheim
- Enrollment
- 218
- Start date
- Apr 2024
- Locations
- 37 sites, United States, Spain
- Primary endpoint
- Relative reduction in liver fat content of at least 30% from baseline to Week 48 (yes/no) assessed by magnetic resonance imaging proton density fat fraction (MRI-PDFF) [%]